Old Web
English
Sign In
Acemap
>
authorDetail
>
Esther Heijnen
Esther Heijnen
Novartis
Medicine
MF59
Immunogenicity
Influenza vaccine
Adverse effect
4
Papers
45
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
MF59-Adjuvanted Seasonal Trivalent Inactivated Influenza Vaccine: Safety and Immunogenicity in Young Children at Risk of Influenza Complications
2019
International Journal of Infectious Diseases
Sanjay S. Patel
Svetlana Bizjajeva
Esther Heijnen
Janine Oberye
Show All
Source
Cite
Save
Citations (8)
Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years
2018
Infection and Chemotherapy
Byung-Wook Yoo
Chang Oh Kim
Allen Izu
Ashwani Kumar Arora
Esther Heijnen
Show All
Source
Cite
Save
Citations (3)
MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico
2018
Human Vaccines & Immunotherapeutics
Aurelio Cruz Valdez
Gabriel Valdez-Zapata
Sanjay S. Patel
Flavia V. Castelli
Marcia G. Garcia
Wim T. Jansen
Ashwani Kumar Arora
Esther Heijnen
Show All
Source
Cite
Save
Citations (16)
Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents
2015
Human Vaccines & Immunotherapeutics
Xavier Sáez-Llorens
Diana Catalina Aguilera Vaca
Katia Abarca
Emmanuelle Maho
Maria Gabriela Graña
Esther Heijnen
Igor Smolenov
Peter M. Dull
Show All
Source
Cite
Save
Citations (18)
1